Skip to main content
SpringerLink
Log in

Neuerungen in der thorakalen Onkologie

NSCLC und SCLC

  • CME Fortbildung
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Reinmuth N. Lungenkrebsscreening - wer, wo und wie? Dtsch Med Wochenschr. 2019;144:1721-5

  2. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409

  3. National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. J Thorac Oncol. 2019;14:1732-42

  4. De Koning HJ, Van Der Aalst CM, De Jong PA et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382:503-13

  5. Becker N, Motsch E, Trotter A et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer. 2020;146(6):1503-13

  6. Reinmuth N, Schumann C. [Fundamental Changes in the Treatment of Lung Cancer]. Pneumologie. 2018;72:732-5

  7. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446-54

  8. Griesinger F, Eberhardt W, Früh M et al. Lungenkarzinom, nicht-kleinzellig (NSCLC). Onkopedia. 2021; https://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht-kleinzellig-nsclc/@@guideline/html/index.html; zugegriffen am 25.5.2021

  9. Planchard D, Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29 Suppl 4:iv192-iv237

  10. Ramalingam SS, Vansteenkiste J, Planchard D et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50

  11. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-53

  12. Camidge R, Kim HR, Ahn M et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Annals of Oncology. 2019; https://doi.org/10.1093/annonc/mdz446

  13. Peters S, Camidge DR, Shaw AT et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(9):829-38

  14. Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015;372:683-4

  15. Planchard D, Besse B, Groen HJM et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984-93

  16. Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378:731-9

  17. Reinmuth N, Merk M, Duell T. Immuntherapie des nichtkleinzelligen Lungenkarzinoms. Onkologe. 2021;27:179-90

  18. Reck M, Rodriguez-Abreu D, Robinson AG et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50 % or Greater. J Clin Oncol. 2019;37:537-46

  19. Brahmer JR, Rodriguez-Abreu D, Robinson AG et al. KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50 %. Ann Oncol. 2020;31:S1142-S1215; Abstract LBA1151

  20. Spigel D, De Marinis F, Giaccone G et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. Ann Oncol. 2019;30(Suppl 5):v915

  21. Sezer A, Kilickap S, Gümüş M et al. LBA52: EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50 %. Ann Oncol. 2020;31(Suppl 4):S1142-S1215; https://doi.org/10.1016/j.annonc.2020.08.2285

  22. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:2078-92

  23. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378:2288-301

  24. Jotte R, Cappuzzo F, Vynnychenko I et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol. 2020;15:1351-60

  25. West H, Mccleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924-37

  26. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379:2040-51

  27. Reck M, Ciuleanu TE, Dols MC et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020;38:abstr 9501

  28. Leighl NB, Laurie SA, Goss GD et al. CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38:abstr 9502

  29. Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563-580

  30. Antonia SJ, Villegas A, Daniel D et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2019;379:2342-50

  31. Faivre-Finn C, Vicente D, Kurata T et al. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial. Ann Oncol. 2020;31:S1142-S1215. Abstract LBA1149

  32. Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378:1976-86

  33. Wakelee HA, Altorki NK, Zhou C et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39:abstr 8500

  34. Wu YL, Tsuboi M, He J et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383:1711-23

  35. Horn L, Mansfield AS, Szczesna A et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379:2220-9

  36. Paz-Ares L, Dvorkin M, Chen Y et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-39

  37. Von Pawel J, Jotte R, Spigel DR et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012-9

  38. Trigo J, Subbiah V, Besse B et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645-54

Download references

Author information

Authors and Affiliations

  1. - Thorakale Onkologie -, Asklepios Fachkliniken München-Gauting, Robert-Koch-Allee 2, 82131, Gauting, Germany

    Niels Reinmuth

  2. Asklepios Fachkliniken München-Gauting, Robert-Koch-Allee 2, 82131, Gauting, Germany

    Martina Merk & Thomas Duell

Authors
  1. Niels Reinmuth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Merk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Duell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niels Reinmuth.

Ethics declarations

Die Autoren erklären, dass bei der Erstellung des Beitrags keine Interessenkonflikte bestanden. Niels Reinmuth erhielt Honorare für Vorträge und Beratungen von Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, Hoffmann-La Roche, MSD, Pfizer, Takeda.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reinmuth, N., Merk, M. & Duell, T. NSCLC und SCLC. Pneumo News 13, 35–43 (2021). https://doi.org/10.1007/s15033-021-2728-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-021-2728-6

Search

Navigation